Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1052]

SABCS 2011: Immediate bisphosphonate use with endocrine therapy reduced recurrence, increased survival in postmenopausal early breast cancer

SABCS 2011: Immediate bisphosphonate use with endocrine therapy reduced recurrence, increased survival in...

Pill and pregnancy have biggest effects on ovarian cancer risk

Pill and pregnancy have biggest effects on ovarian cancer risk

Role of fat in assessing breast cancer risk

Role of fat in assessing breast cancer risk

EMCC 2011: Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women

EMCC 2011: Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women

EMCC 2011: Aromatase inhibitor letrozole guards against breast cancer relapse for up to eight years

EMCC 2011: Aromatase inhibitor letrozole guards against breast cancer relapse for up to eight years

EMCC 2011: Breast cancer tumour make-up changes through the course of disease; regular biopsies needed to ensure correct treatment

EMCC 2011: Breast cancer tumour make-up changes through the course of disease; regular biopsies needed to ensure...

Zytiga approved in the EU for metastatic castration-resistant prostate cancer

Zytiga approved in the EU for metastatic castration-resistant prostate cancer

Adjuvant therapy may not be necessary for older breast cancer patients

Adjuvant therapy may not be necessary for older breast cancer patients

PET scans confirm effectiveness of oestrogen-blocking drugs in patients with metastatic breast cancer

PET scans confirm effectiveness of oestrogen-blocking drugs in patients with metastatic breast cancer

Toxicity of aromatase inhibitors may explain lack of overall survival improvement

Toxicity of aromatase inhibitors may explain lack of overall survival improvement

More from ecancer